Elanco Animal Health (ELAN) Non-Current Debt (2018 - 2026)
Elanco Animal Health (ELAN) reported Non-Current Debt of $3.7 billion for Q1 2026, down 14.13% on a YoY basis from $4.4 billion in Q1 2025, and down 0.69% sequentially from $3.8 billion in Q4 2025.
Elanco Animal Health (ELAN) Non-Current Debt (2018 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 9 years of Non-Current Debt data on file, last reported at $3.7 billion in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Debt fell 14.13% year-over-year to $3.7 billion; the trailing twelve-month figure through Mar 2026 stood at $3.7 billion (down 14.13% YoY), and the FY2025 full-year result was $3.8 billion, down 12.04% from the prior year.
- Non-Current Debt slipped to $3.7 billion in Q1 2026, from $3.8 billion in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $6.1 billion in Q1 2022 to a low of $3.7 billion in Q1 2026.
- A 5-year average of $5.0 billion and a median of $5.4 billion in 2022 frame the typical range for Non-Current Debt.
- Across the five-year window, Non-Current Debt advanced 5.98% in 2023 and slipped 28.72% in 2024, its largest moves.
- Tracing ELAN's Non-Current Debt over 5 years: stood at $5.4 billion in 2022, then gained by 5.98% to $5.8 billion in 2023, then declined by 25.93% to $4.3 billion in 2024, then dropped by 12.04% to $3.8 billion in 2025, then retreated by 0.69% to $3.7 billion in 2026.
- Business Quant data shows ELAN's Non-Current Debt at $3.7 billion in Q1 2026, $3.8 billion in Q4 2025, and $4.0 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 197.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.74 Bn |
| Dec 31, 2025 | 3.76 Bn |
| Sep 30, 2025 | 3.96 Bn |
| Jun 30, 2025 | 4.15 Bn |
| Mar 31, 2025 | 4.35 Bn |
| Dec 31, 2024 | 4.28 Bn |
| Sep 30, 2024 | 4.36 Bn |
| Jun 30, 2024 | 4.32 Bn |
| Mar 31, 2024 | 5.73 Bn |
| Dec 31, 2023 | 5.77 Bn |
| Sep 30, 2023 | 5.87 Bn |
| Jun 30, 2023 | 6.06 Bn |
| Mar 31, 2023 | 5.64 Bn |
| Dec 31, 2022 | 5.45 Bn |
| Sep 30, 2022 | 5.90 Bn |
| Jun 30, 2022 | 6.01 Bn |
| Mar 31, 2022 | 6.13 Bn |
| Dec 31, 2021 | 6.32 Bn |
| Sep 30, 2021 | 6.33 Bn |
| Jun 30, 2021 | 6.10 Bn |